• Vaccine Name: Brucella ovis BLSOmp31 subunit vaccine
• Target Pathogen: Brucella spp.
• Target Disease: Brucellosis
• Vaccine Ontology ID: VO_0009484
• Type: Subunit vaccine
• Status: Research
• Host Species for Licensed Use: Sheep
• Host Species as Laboratory Animal Model: Mus musculus (Balb/c mice)
• Antigen: BLSOmp31
• Adjuvant: class B CpG-ODN | ISPA (modified ISCOMATRIX)
• Preparation: BLSOmp31 formulated with class B CpG-ODN in a nanostructure called Coa-ASC16; compared with BLSOmp31 alone, BLSOmp31 with CpG-ODN, and BLSOmp31 emulsified in Incomplete Freund Adjuvant. (Moran et al, 2021)
  Polymeric BLSOmp31 antigen formulated with ISPA adjuvant. (Moran et al, 2022)
• Description: This study tested a new delivery system for mucosal immunization with BLSOmp31 in a murine model to improve efficacy over previous formulations. Efficacy: BLSOmp31/CpG-ODN/Coa-ASC16 administered subcutaneously conferred significant protection against B. ovis challenge; ocular administration showed a similar degree of protection (3.66 and 3.60 logs of protection, respectively). Immune response: Subcutaneous administration stimulated a mixed Th1-Th2 immune response with highest IFN-…£ levels; induced mixed IgG1/IgG2a antibodies; ocular route induced lower serum IgG and IgA, less IFN-…£ and IL-4; no antibodies detected in vaginal lavages or saliva; fecal antigen-specific IgA slightly higher with subcutaneous route. (Moran et al, 2021)
  BLSOmp31 was previously identified as a protective immunogen against Brucella ovis. In this study, it was formulated with a modified ISCOMATRIX adjuvant called ISPA and administered by subcutaneous and ocular routes. Efficacy: Both subcutaneous and ocular immunization routes significantly protected mice against Brucella ovis infection. Immune response: Immunization induced significantly higher IgG antibody levels with a mixed Th1/Th2 profile; IgA and IgG detected in sera and various mucosal secretions; opsonic antibodies enhanced uptake of labeled Brucella ovis by neutrophils and monocytes; subcutaneous immunization induced highest IFN-…£ levels; ocular immunization induced significant IFN-…£ and IL-4 levels compared to non-immunized controls. (Moran et al, 2022)

Mouse Response

• Host Strain: Balb/c
• Immune Response: Subcutaneous administration stimulated a mixed Th1-Th2 immune response with highest IFN-ɣ levels; induced mixed IgG1/IgG2a antibodies; ocular route induced lower serum IgG and IgA, less IFN-ɣ and IL-4; no antibodies detected in vaginal lavages or saliva; fecal antigen-specific IgA slightly higher with subcutaneous route. (Moran et al, 2021)
• Challenge Protocol: Protective efficacy was evaluated in Balb/c mice challenged with Brucella ovis after subcutaneous or ocular administration of the vaccine formulations. (Moran et al, 2021)
• Efficacy: BLSOmp31/CpG-ODN/Coa-ASC16 administered subcutaneously conferred significant protection against B. ovis challenge; ocular administration showed a similar degree of protection (3.66 and 3.60 logs of protection, respectively). (Moran et al, 2021)
• Description: Protective efficacy was evaluated in Balb/c mice challenged with Brucella ovis after subcutaneous or ocular administration of the vaccine formulations. (Moran et al, 2021)

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: BALB/c mice were immunized with the BLSOmp31–ISPA vaccine formulation using subcutaneous or ocular delivery. (Moran et al, 2022)
• Immune Response: Immunization induced significantly higher IgG antibody levels with a mixed Th1/Th2 profile; IgA and IgG detected in sera and various mucosal secretions; opsonic antibodies enhanced uptake of labeled Brucella ovis by neutrophils and monocytes; subcutaneous immunization induced highest IFN-ɣ levels; ocular immunization induced significant IFN-ɣ and IL-4 levels compared to non-immunized controls. (Moran et al, 2022)
• Efficacy: Both subcutaneous and ocular immunization routes significantly protected mice against Brucella ovis infection. (Moran et al, 2022)
• Description: Immunization of BALB/c mice by subcutaneous and ocular routes; evaluation of systemic and mucosal immune responses, opsonic antibody activity, and protection against Brucella ovis infection. (Moran et al, 2022)